Scope and patent landscape for US Patent 10,010,530 covering crystalline forms I/I′/I″ and preparation of N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
US Patent 10,010,530 is directed to specific crystalline polymorphs of a single, named small-molecule API (three stereochemically defined “crystalline forms” labeled I, I′, I″) plus a tightly constrained crystallization process to make those forms. Claim scope is dominated by: (1) X-ray powder diffraction (XRPD) peak lists as positive identity criteria, and (2) process parameters (acetonitrile:water ratio, cooling window, and vacuum drying temperature) that narrow design-around space for manufacturers.
The claims you provided cluster into two enforceable buckets: crystalline product-by-characterization claims (claims 1–3 and 11–13) and process claims (claims 4–10). The practical IP risk for generics is therefore primarily formulation/manufacturing control and evidence of non-infringement via XRPD, not route-of-synthesis of the underlying freebase/compound scaffold.
What crystalline forms does US 10,010,530 claim, and what exact XRPD peaks define infringement?
Featured snippet answer:
US 10,010,530 defines infringement for polymorphs I, I′, I″ by XRPD characteristic peaks at specified 2-theta angles. Independent claims 1–3 each list a core set of peaks; dependent claims 11–13 add a second set of peaks for the same forms.
Claim 1: Crystalline form I (XRPD fingerprint)
- API: N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl) propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I)
- XRPD characteristic peaks (about, 2-theta):
- 8.5, 10.4, 16.6, 16.9, 24.3
Claim 2: Crystalline form I′ (XRPD fingerprint)
- API stereochemistry: 5-((S)-1-hydroxyethyl) variant
- XRPD characteristic peaks (about, 2-theta):
- 9.3, 15.7, 17.0, 24.1, 25.1
Claim 3: Crystalline form I″ (XRPD fingerprint)
- API stereochemistry: 5-((R)-1-hydroxyethyl) variant
- XRPD characteristic peaks (about, 2-theta):
- 9.2, 10.9, 15.1, 15.8, 22.1
Dependent claims add additional peak sets
These “further having” provisions increase evidentiary hooks for enforcement and can make ambiguity harder for defendants attempting to show that a sample “does not match” the claimed polymorph.
- Claim 11 (Form I) adds:
- 9.7, 15.9, 19.2, 21.8, 25.5
- Claim 12 (Form I′) adds:
- 11.4, 14.9, 17.7, 20.5, 27.2
- Claim 13 (Form I″) adds:
- 7.9, 16.9, 18.4, 20.2, 21.8
Scope implications for enforcement
- XRPD-anchored definition: The crystalline forms are defined by peak lists rather than by unit cell parameters, solvent composition, or “process trace.” That shifts the infringement battle to analytical characterization.
- “About” language: The claims use “about” peak positions. That typically gives the patentee flexibility on measurement tolerances, but the exact infringement tolerance is still a factual/technical question driven by method, instrument, sample preparation, and peak picking.
- Overlap risk between forms: Because each form has a partly different peak set, a defendant can attempt to show their material has a different polymorph mix or missing peaks. But the dependent claims expand the fingerprint, raising the probability that a true matching material will satisfy multiple peak criteria simultaneously.
How narrow is the process claim scope for making crystalline forms I/I′/I″?
Featured snippet answer:
The process claims require: mixing the relevant starting material with acetonitrile/water, heating to form a solution, cooling to 0–50°C, and isolating the crystals, with additional narrowing via acetonitrile:water ratios (85:15 to 99:1), a cooling duration (5–24 hours), and vacuum drying at 40–60°C.
Independent process claim 4
A process for preparing crystalline form I, I′, or I″, respectively, comprising:
a) Mix:
- N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl) propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I)
OR
- N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((S)-1-hydroxyethyl)-1H-pyrazole-3-carboxamide (Ia)
OR
- N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((R)-1-hydroxyethyl)-1H-pyrazole-3-carboxamide (Ib)
with a mixture of acetonitrile and water.
b) Heat to form a solution
c) Cool from the solution to about 0–50°C
d) Isolate the crystalline form
Dependent process claim 5: acetonitrile:water ratio
Dependent process claim 6: narrower ratio
Dependent process claim 7: specific ratio
Dependent process claim 8: cooling duration
Dependent process claim 9: narrower duration
Dependent process claim 10: vacuum drying
- dried under vacuum at about 40°C to about 60°C
Scope implications for “route” and “scale-up”
- The core crystallization conditions are not open-ended: they are solvent-system-limited (acetonitrile/water only) and parameter constrained (composition, cooling range, cooling time, drying temperature).
- Manufacturers using a different anti-solvent system (e.g., ethanol/water, acetone/water, IPA/water), a different cooling profile, or drying outside 40–60°C can attempt to argue non-infringement of dependent claims, and potentially of independent claim 4 if the process does not fall within “acetonitrile and water” mixing plus the full required steps.
- Claim 4 still hinges on “mixing … with a mixture of acetonitrile and water” and the defined cooling range. Changing only the solvent ratio outside 85:15 to 99:1 may avoid dependent claims 5–7 but not necessarily independent claim 4 if the independent claim does not explicitly lock the ratio. In your claim text, independent claim 4 does not specify the ratio, so infringement could still occur even if the ratio lies outside 85:15 to 99:1, unless a court construes “acetonitrile and water” plus heating/cooling to 0–50°C as still producing the claimed form.
What is the practical “claim coverage” for product supply: direct crystalline possession vs process manufacturing?
Product claims (1–3, 11–13)
These claims cover the crystalline forms themselves, not necessarily how they are made. Even if a manufacturer uses a different route, they can infringe if the marketed API batch is determined to be the claimed polymorphs by XRPD.
Process claims (4–10)
These claims cover manufacturing steps. Even if the defendant’s final polymorph is disputed, the process claims can be asserted where manufacturing records and analytical samples align with the claimed process parameters.
Combined litigation posture
- Typical enforcement strategy for polymorph patents blends both: assert product-by-XRPD to capture “what was made,” and process to capture “how it was made.”
How to assess freedom-to-operate from these claims alone (design-around levers that matter)
1) XRPD fingerprint avoidance
A generic or contract manufacturer can attempt to produce:
- a different polymorph,
- a polymorph mixture that fails to meet the core peak lists in claims 1–3, or
- the same “form” but with XRPD peak intensities/positions outside the “about” tolerances under the lab’s method.
The risk point is that the dependent claims 11–13 provide additional peaks that can make it harder to deny identity if the sample matches both the independent and dependent sets.
2) Solvent system deviation
Changing the crystallization solvent system away from acetonitrile/water is a direct route to avoid claim 4 because claim 4 requires that specific solvent mixture is used in step a).
3) Cooling profile deviation
- Avoid cooling to about 0–50°C (claim 4) and/or adjust duration outside 5–24 hours (claim 8) or 6–12 hours (claim 9).
- If production uses controlled nucleation and immediate isolation without the claimed cooling window, process claim 4 still requires cooling as recited.
4) Drying temperature deviation
- Avoid vacuum drying at about 40–60°C to defeat claim 10 specifically.
5) Ratio deviation
- Ratio is only explicitly narrowed in claims 5–7. If defendants keep the ratio outside those dependent ranges but remain within the broad acetonitrile/water mixing of claim 4, they may still face independent claim 4 risk.
What patent landscape conclusions can be drawn from the claim set provided?
Landscape strength indicators embedded in the claim drafting
- Polymorph-by-XRPD strategy: This is a classic approach to obtain broad product protection for a defined solid form. It tends to be enforceable even where the underlying API synthesis is generic.
- Process scaffolding present: Claims 4–10 provide manufacturing hooks that can support injunction leverage if defendants can be shown to use essentially the same crystallization recipe.
- Tight parameterization: The presence of specific solvent ratios, cooling times, and vacuum drying temperature narrows the process-space and creates clearer evidence targets.
But what cannot be concluded from the claims alone
No expiration date, priority chain, listed assignees, continuation status, prosecution history, or co-pending family members can be derived from the claim text you provided. Likewise, infringement risk against specific competitors cannot be mapped without linking to:
- the Orange Book listing for the relevant drug product,
- FDA submissions and ANDA/505(b)(2) references,
- and the actual XRPD results for competitor lots.
Under the constraint that only sufficient information should be used to produce a complete and accurate response, those landscape items are not provided here.
Key Takeaways
- US 10,010,530 protects three crystalline polymorphs of a specific stereochemically defined pyrazole carboxamide API, with XRPD peak lists as the core claim-defining feature.
- Claims 1–3 define the main infringement fingerprint by five peaks each; claims 11–13 add five additional peaks each, expanding the analytical match burden.
- Claims 4–10 cover a solvent- and temperature-defined crystallization process using acetonitrile/water, cooling to ~0–50°C, with further limitations on solvent ratio, cooling duration, and vacuum drying at ~40–60°C.
- For generic freedom-to-operate, the decisive factors are (a) whether the manufactured API is analytically the claimed polymorph(s) and (b) whether manufacturing uses the claimed acetonitrile/water crystallization conditions.
FAQs
1) How do “about” XRPD peak ranges affect infringement arguments for crystalline polymorph patents?
They generally introduce tolerance-based interpretation around 2-theta positions, with infringement hinging on method, instrument calibration, and peak picking consistent with the patent’s characterization approach.
2) Can a manufacturer avoid infringement of claims 5–7 by changing the acetonitrile:water ratio but keeping acetonitrile/water as the solvent system?
It can avoid dependent claims 5–7, but independent claim 4 may still be implicated because it does not specify those ratio ranges in your provided text.
3) If a company makes the claimed crystalline form using a different solvent system, does US 10,010,530 still apply?
Product claims (1–3, 11–13) can still apply if the final material matches the claimed XRPD fingerprints, independent of how it was made.
4) What is the highest-risk manufacturing step under claims 8–10 for scale-up?
Cooling duration and drying conditions: claim 8 (5–24 hours), claim 9 (6–12 hours), and claim 10 (vacuum drying at ~40–60°C) can be hard to match exactly when scaling due to heat transfer and solvent mass balance.
5) Which claim set is better for proving “what was made” versus “how it was made”?
Claims 1–3 (and 11–13) are stronger for “what was made” via XRPD; claims 4–10 are stronger for “how it was made” via crystallization process parameters.
References
- United States Patent No. 10,010,530. Claims provided in prompt (polymorphs I/I′/I″ and processes using acetonitrile/water, cooling to 0–50°C, and vacuum drying 40–60°C).
